onapristone: Clinical Trials

6 trials of onapristone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 2 unknown, 1 completed, 1 withdrawn. 5 Phase 2, 4 Phase 1, 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Terminated 2, Unknown 2, Withdrawn 1
Phase 14Unknown 2, Terminated 1, Withdrawn 1
Early Phase 11Completed 1

Follow onapristone: new trials by email Literature Review of onapristone trials Research Report on onapristone

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
Elacestrant, Onapristone - Breast Cancer
Phase 1 / Phase 2WithdrawnContext Therapeutics Inc.2023-06-012025-04-22
Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
Elacestrant, Onapristone - Breast Cancer
Phase 1 / Phase 2TerminatedContext Therapeutics Inc.42022-12-022026-07-21
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
Onapristone, Fulvestrant - ER-positive Breast Cancer, HER2-negative Breast Cancer
Phase 2TerminatedUniversity of Wisconsin, Madison112021-10-052024-05-03
Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer
Onapristone - Breast Cancer
Early Phase 1CompletedSOLTI Breast Cancer Research Group102020-11-062022-04-01
Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer
onapristone, abiraterone - Prostate Cancer, Metastatic Prostate Cancer
Phase 1 / Phase 2UnknownArno Therapeutics752014-02-012015-06-24
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
onapristone - Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy
Phase 1 / Phase 2UnknownArno Therapeutics602014-01-012015-06-24

Conditions studied

Breast Neoplasms (4)  ·  Endometrial Neoplasms (1)  ·  Genital Diseases, Male (1)  ·  Genital Neoplasms, Male (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Ovarian Neoplasms (1)  ·  Prostatic Diseases (1)  ·  Prostatic Neoplasms (1)  ·  Urogenital Neoplasms (1)

Sponsors

Arno Therapeutics (2)  ·  Context Therapeutics Inc. (2)  ·  SOLTI Breast Cancer Research Group (1)  ·  University of Wisconsin, Madison (1)

Countries

United States (3)  ·  France (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Kari B Wisinski, MD (1)  ·  Paul H Cottu, MD (1)  ·  Sailaja Kamaraju, MD, MS (1)

Results publications

PMID 30304013, PMID 42215464

NIH funding

2019 (1)